REG - Gooch & Housego PLC - Site Visit to ITL Life Science Business

Gooch & HousegoAnnouncement

09/01/2019 07:00

RNS Number : 5568M
Gooch & Housego PLC
09 January 2019
 









 9 January 2019



 
 
 
Gooch & Housego PLC
("Gooch & Housego" or the "Company")
 
Site Visit to ITL Life Science Business
Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components and systems, is today hosting a site visit for institutional investors and analysts at the Company's ITL life science business in Ashford, Kent.
ITL designs, develops and manufactures high quality medical and in vitro diagnostic (IVD) devices. It was acquired by Gooch & Housego in August 2018 as part of the Company's strategic expansion in the life sciences sector and its move towards system-level products.
The site visit will provide some insight into ITL, and its system-based capabilities, and include a brief overview of the Company's broader activities in the life sciences/biophotonics sector.
The short slide pack accompanying the site visit will be made available on the Company's website: http://goochandhousego.com/investors/.
No new material information will be disclosed.
 



 
For further information contact: -
 












Mark Webster / Andrew Boteler 


Gooch & Housego PLC


01460 256440




Mark Court / Sophie Wills / Catriona Flint 


Buchanan


020 7466 5000




Patrick Robb / David Anderson   


Investec Bank plc


020 7597 5970



 
 
 
 
Notes to editors
 
1.     Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGUBWGUPBGMR